QUREMEDIUM SIGNALFINANCIAL10-K

QURE shows meaningfully declined revenue alongside substantial increases in working capital components, indicating operational transition challenges following strategic divestitures.

The company appears to be navigating a significant business transition, with revenue declining substantially while simultaneously building up inventory and receivables positions. The improved net income despite lower revenue suggests better cost management, but the overall financial profile indicates operational uncertainty that investors should monitor closely.

Comparing 2026-03-02 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

QURE's financial position reflects a company in transition, with revenue declining meaningfully to $13.1M while current assets expanded substantially to $656M, driven by notable increases in inventory and accounts receivable. Despite lower revenues, the company improved its net loss position and maintained a solid asset base, though cash reserves declined to $80.2M from $158.9M. The dramatic reduction in capital expenditures alongside increased working capital suggests the company is reallocating resources while managing through strategic changes.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-87%
$3.4M→$439K

Capex reduced 87% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Accounts Receivable
Balance Sheet
+79.8%
$3.7M→$6.6M

Receivables surged 79.8% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Inventory
Balance Sheet
+73.7%
$6.9M→$12.0M

Inventory surged 73.7% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
+68.1%
$390.3M→$656.0M

Current assets grew 68.1% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
+57.1%
$40.1M→$62.9M

Current liabilities surged 57.1% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-49.5%
$158.9M→$80.2M

Cash declined 49.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Assets
Balance Sheet
+48.2%
$556.5M→$824.9M

Asset base grew 48.2% — expansion through organic growth, acquisitions, or capital deployment.

Revenue
P&L
-47.8%
$25.1M→$13.1M

Revenue declined 47.8% — significant demand weakness or market share loss warrants investigation.

SG&A Expense
P&L
+24.3%
$52.7M→$65.5M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Net Income
P&L
+16.9%
-$239.6M→-$199.0M

Net income grew 16.9% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-02-27
ADDED
As of February 26, 2026, the registrant had 62,529,408 ordinary shares, par value 0.05, outstanding.
If we are unable to successfully commercialize our product candidates or experience significant delays in doing so, including as result of a BLA or other key regulatory filings being delayed or rejected, our business could be materially harmed.
Disruptions or changes at the FDA, or other government agencies, as a result of funding cuts, personnel losses, leadership changes, regulatory changes or regulatory reform, government shutdowns and other developments could hinder the timing of or our ability to obtain further guidance from the FDA regarding our clinical development programs and secure approval of our product candidates in a timely manner, which could adversely affect our business.
We may leverage certain specialized regulatory pathways and designations, such as the FDA s accelerated approval pathway, Regenerative Medicine Advance Therapy ( RMAT ) designation and Breakthrough Therapy designation, to develop our product candidates or to seek licensure.
Our business development and strategic initiatives, acquisitions, partnerships, collaborations or other transactions, may not achieve their intended benefits or goals and may result in additional risks to our business.
+7 more — sign up free →
REMOVED
As of February 24, 2025, the registrant had 54,076,880 ordinary shares, par value 0.05, outstanding.
If we are unable to successfully commercialize our product candidates or experience significant delays in doing so, our business could be materially harmed.
We may leverage certain specialized regulatory pathways and designations, such as the FDA s accelerated approval pathway and RMAT designation, to develop our product candidates or to seek licensure.
Our business development and strategic initiatives, including divestitures such as the Lexington Transaction, acquisitions, partnerships, collaborations or other transactions, may not achieve their intended benefits or goals and may result in additional risks to our business.
We may not be successful in obtaining rights from external parties to new product candidates and key technologies, or in securing partnerships to support the development or commercialization of our product candidates.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →